2nd International Conference on Fostering Interdisciplinary Research In Health Sciences (ICFIRHS) 2019 (01-May-2019)        |

Journal :   Research Journal of Pharmacy and Technology

Volume No. :   12

Issue No. :  6

Year :  2019

Pages :   2999-3006

ISSN Print :  0974-3618

ISSN Online :  0974-360X


Allready Registrered
Click to Login

Development of New Src Inhibitors

Address:   Samar Alnukari1*, Faten Sliman2
1Master Student in Pharmaceutics and Pharmaceutical Technology Department, Faculty of Pharmacy, Tishreen University, Syria.
2Doctor in Pharmaceutical Chemistry Department, Faculty of Pharmacy, Tartous University, Syria.
*Corresponding Author
DOI No: 10.5958/0974-360X.2019.00507.9

Protein kinase, especially tyrosine kinase Src, is considered as an important target for cancer therapy such as lung, prostate and central nervous system cancers, as well as its involvement in tumor metastasis. The aim of this study was to find effective and selective inhibitors of Src protein kinase using molecular modeling study, a library of chemical compounds derived from purine and Theophylline cores was then docked within the active site of the Src enzyme. The link affinity and the attitudes of binding of the suggested compounds with the active site of the previously prepared Src enzyme were determined of these compounds. The study led to three effective and highly selective compounds on the Src enzyme; two compounds derived from the Purine core Pur46 and Pur49 and one compound derived from Theophylline core Theo21. The study was completed by chemical synthesis of Theo23 molecule.
Tyrosine Kinase, Molecular Modeling, Docking, Src, Cancer.
Samar Alnukari, Faten Sliman. Development of New Src Inhibitors. Research J. Pharm. and Tech. 2019; 12(6):2999-3006.
[View HTML]     

Visitor's No. :   594759